Details for New Drug Application (NDA): 076723
✉ Email this page to a colleague
NDA 076723 describes HYDROMORPHONE HYDROCHLORIDE, which is a drug marketed by Barr, Hikma, Hospira, Hospira Inc, Rising, Watson Labs, Ascent Pharms Inc, Chartwell, Actavis Labs Fl Inc, Osmotica Pharm Us, Padagis Us, Aurolife Pharma Llc, Nesher Pharms, Nostrum Labs Inc, and Specgx Llc, and is included in twenty-four NDAs. It is available from fifteen suppliers. Additional details are available on the HYDROMORPHONE HYDROCHLORIDE profile page.
The generic ingredient in HYDROMORPHONE HYDROCHLORIDE is hydromorphone hydrochloride. There are fourteen drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the hydromorphone hydrochloride profile page.
The generic ingredient in HYDROMORPHONE HYDROCHLORIDE is hydromorphone hydrochloride. There are fourteen drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the hydromorphone hydrochloride profile page.
Summary for 076723
| Tradename: | HYDROMORPHONE HYDROCHLORIDE |
| Applicant: | Nostrum Labs Inc |
| Ingredient: | hydromorphone hydrochloride |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 076723
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 8MG | ||||
| Approval Date: | Oct 18, 2005 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
